Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free EXAS Stock Alerts $53.70 -0.30 (-0.56%) (As of 02:16 PM ET) Add Compare Share Share Today's Range$52.91▼$55.1450-Day Range$53.51▼$74.2652-Week Range$52.25▼$100.77Volume1.65 million shsAverage Volume2.43 million shsMarket Capitalization$9.91 billionP/E RatioN/ADividend YieldN/APrice Target$95.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exact Sciences alerts: Email Address Exact Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside75.9% Upside$95.40 Price TargetShort InterestHealthy4.81% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.28Based on 42 Articles This WeekInsider TradingSelling Shares$4.26 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.01) to ($0.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.54 out of 5 starsMedical Sector92nd out of 928 stocksMedical Laboratories Industry5th out of 21 stocks 3.5 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageExact Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Exact Sciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.81% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exact Sciences has recently decreased by 10.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 1.8 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 42 news articles for Exact Sciences this week, compared to 8 articles on an average week.Search InterestOnly 20 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -6% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,255,377.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($1.01) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -41.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -41.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exact Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Exact Sciences Stock (NASDAQ:EXAS)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesMay 3, 2024 | insidertrades.comExact Sciences Co. (NASDAQ:EXAS) CEO Kevin T. Conroy Sells 1,155 SharesMay 15 at 4:29 AM | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Short Interest Down 10.2% in AprilMay 13 at 6:52 AM | americanbankingnews.comBTIG Research Lowers Exact Sciences (NASDAQ:EXAS) Price Target to $80.00May 13 at 2:40 AM | americanbankingnews.comLeerink Partnrs Weighs in on Exact Sciences Co.'s Q2 2024 Earnings (NASDAQ:EXAS)May 12 at 3:50 AM | americanbankingnews.comLeerink Partnrs Equities Analysts Reduce Earnings Estimates for Exact Sciences Co. (NASDAQ:EXAS)May 11, 2024 | finance.yahoo.comExact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 10, 2024 | finance.yahoo.comExact Sciences Corp (EXAS) Q1 2024 Earnings: Revenue Growth Amidst Increased Net LossMay 10, 2024 | markets.businessinsider.comOptimistic Outlook for Exact Sciences: Overcoming Challenges with Growth Initiatives and New Product PotentialMay 10, 2024 | finance.yahoo.comExact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 10, 2024 | businesswire.comThe National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer PatientsMay 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences on Strong Performance and Promising Growth InitiativesMay 9, 2024 | markets.businessinsider.comBuy Rating Reiterated for Exact Sciences on Strong Q1 Performance and Positive Financial OutlookMay 9, 2024 | finance.yahoo.comQ1 2024 Exact Sciences Corp Earnings CallMay 9, 2024 | finance.yahoo.comExact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comExact Sciences Stock, A Cathie Wood Darling, Tumbles On 'Overblown' Growth ConcernsMay 9, 2024 | benzinga.comExact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionMay 9, 2024 | finance.yahoo.comExact Sciences Corp (EXAS) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences Amidst Strong Growth and Innovative PipelineMay 9, 2024 | msn.comExact Sciences (EXAS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comExact Sciences Announces First-Quarter 2024 ResultsMay 8, 2024 | msn.comExact Sciences GAAP EPS of -$0.60 misses by $0.11, revenue of $637.52M beats by $10.71MMay 8, 2024 | msn.comExact Sciences Stock Plunges On Q1 Earnings: What You Need To KnowMay 7, 2024 | finance.yahoo.comExact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024May 1, 2024 | businesswire.comExact Sciences to Participate in May Investor ConferenceSee More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today5/15/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$95.40 High Stock Price Target$121.00 Low Stock Price Target$80.00 Potential Upside/Downside+76.7%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-9.48% Pretax Margin-9.38% Return on Equity-7.12% Return on Assets-3.46% Debt Debt-to-Equity Ratio0.66 Current Ratio1.64 Quick Ratio1.45 Sales & Book Value Annual Sales$2.53 billion Price / Sales3.93 Cash Flow$0.02 per share Price / Cash Flow3,141.97 Book Value$17.39 per share Price / Book3.11Miscellaneous Outstanding Shares184,530,000Free Float182,131,000Market Cap$9.96 billion OptionableOptionable Beta1.26 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 58)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 46)EVP & CFO Comp: $518.13kMs. Sarah Condella (Age 43)Executive Vice President of Human Resources Comp: $742.76kMr. Everett V. Cunningham (Age 58)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 52)Chief Science Officer Mr. Nassar NizamiChief Information OfficerMs. Megan JonesAssociate Manager of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 44)Senior VP, General Counsel & Secretary Mr. Vic ParkerHead of SalesMore ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHNateraNASDAQ:NTRAExelixisNASDAQ:EXELQuest DiagnosticsNYSE:DGXSyneos HealthNASDAQ:SYNHView All CompetitorsInsiders & InstitutionsPEAK6 Investments LLCSold 2,593 shares on 5/15/2024Ownership: 0.002%Gagnon Securities LLCBought 2,654 shares on 5/14/2024Ownership: 0.039%Natixis Investment Managers InternationalBought 430 shares on 5/14/2024Ownership: 0.001%Shell Asset Management Co.Sold 1,485 shares on 5/14/2024Ownership: 0.001%EntryPoint Capital LLCBought 977 shares on 5/14/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions EXAS Stock Analysis - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price target for 2024? 13 Wall Street research analysts have issued 1 year target prices for Exact Sciences' shares. Their EXAS share price targets range from $80.00 to $121.00. On average, they expect the company's stock price to reach $95.40 in the next twelve months. This suggests a possible upside of 75.9% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2024? Exact Sciences' stock was trading at $73.98 at the start of the year. Since then, EXAS shares have decreased by 26.7% and is now trading at $54.23. View the best growth stocks for 2024 here. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our EXAS earnings forecast. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.26. The medical research company had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative net margin of 9.48% and a negative trailing twelve-month return on equity of 7.12%. Exact Sciences's revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.72) EPS. What ETFs hold Exact Sciences' stock? ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Tema Oncology ETF (CANC), First Trust NYSE Arca Biotechnology Index Fund (FBT), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC), Putnam BioRevolution ETF (SYNB) and VanEck Biotech ETF (BBH). What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.65%), Capital World Investors (7.06%), Champlain Investment Partners LLC (1.22%), Sumitomo Mitsui Trust Holdings Inc. (1.09%), Baillie Gifford & Co. (0.93%) and Nikko Asset Management Americas Inc. (0.83%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Daniel J Levangie, Everett Cunningham, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy and Sarah Condella. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More This page (NASDAQ:EXAS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport SocietyTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
